CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 29 target
Drug / intervention
Apatinib +2 moredrug
Likely dose
Apatinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03735082
NCT03735082Phase 2Unknown
CompareCT.gov

The Efficacy and Safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer :Single Arm, Phase II Clinical Trail

Chinese Academy of Medical Sciences·interventional·Posted Nov 8, 2018·Updated Nov 8, 2018

In Brief

A Phase 2 clinical trial evaluating Apatinib, Paclitaxel, and 1 other intervention for Breast Cancer. Targeting 29 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedNov 8, 2018
Enrollment StartNov 1, 2018
Primary CompletionJun 1, 2020
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 7.6 years ago

Interventions

Apatinibdrug

apatinib 250mg,qd,d1-14,14day/cycle

Paclitaxeldrug

paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle

Carboplatindrug

carboplatin AUC=4,d1,14day/cycle;